Curriculum vitae

PERSONAL INFORMATIONS

Giulia Galli

Sex Female | Birthdate 25/12/1988 | Nationality Italian

WORK EXPERIENCE

21/01/2020

Professional collaboration

IRCCS Istituto Nazionale dei Tumori Foundation
via G. Venezian, 1, 20133 Milan

Medical Oncology department –Thoracic Oncology unit

12/2014–12/2019

Residency training in Medical Oncology

IRCCS Istituto Nazionale dei Tumori Foundation
via G. Venezian, 1, 20133 Milan

Medical Oncology department –Thoracic Oncology unit

02/2014–08/2014

Internship

IRCCS Istituto Nazionale dei Tumori Foundation
via G. Venezian, 1, 20133 Milan

Medical Oncology department – Medical Oncology 1 unit

02/2011–07/2013

Clerkship

IRCCS Istituto Nazionale dei Tumori Foundation
via G. Venezian, 1, 20133 Milan

Medical Oncology department – Medical Oncology 1 unit

EDUCATION AND TRAINING

12/2014-18/12/2019

Specialization in Medical Oncology

Università degli Studi di Milano

Thesis: "Impact of lipid metabolism on outcome of patients with advanced non small cell lung cancer treated with immunotherapy"

Supervisor: Prof. Filippo de Braud – Co-supervisor: Dr. Marina Chiara Garassino

10/2018

Start of PhD program in Clinical Resarch

Università degli Studi di Milano

Project: "Improving treatment strategies in thymic epithelial tumors: a TYME collaborative effort"

Supervisor: Prof. Filippo de Braud – Co-supervisor: Dr.ssa Marina Chiara Garassino

09/2013–02/2014

Italian medical lincensing examination

09/2007–17/07/2013

Graduation in Medicine and Surgery

Livello 7 QEQ

Università degli Studi di Milano
via Festa del Perdono, 7, 20122 Milan

Thesis: "Lo studio ASTER: esperienza monoistituzionale di trattamento chemioterapico sequenziale per il carcinoma mammario operabile"("The ASTER trial: single Institution experience of sequential

chemotherapy for operable breast cancer")
Supervisor: Prof. Alessandro Massimo Gianni
Final mark: 110/110 *cum laude*

09/2002–07/2007 **High school diploma** Livello 4 QEQ

Liceo Ginnasio Statale S. M. Legnani
via Volonterio, 34, 21047 Saronno

High school with qualification in classical studies
Final mark: 100/100

PERSONAL SKILLS

Mother tongue: Italian

Other languages

	COMPREHENSION		SPEAKING		WRITING
	Listening	Reading	Interaction	Oral production	
English	C1	C2	C1	C1	B2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Advanced user
Common European Framework Reference for Languages

Driving license: B

FURTHER INFORMATIONS

Experience abroad: ESMO Fellowship - Translational Research Unit visit - Wien General Hospital (May 2019)

Affiliations:
European Society of Medical Oncology (ESMO)
American Society of Clinical Oncology (ASCO)
Italian Association of Medical Oncology (AIOM)
International Association for the Study of Lung Cancer (IASLC)

Certifications:
Good Clinical Practice (GCP) certificate
IELTS Academic certificate of proficiency in English language (26/04/2018)

Honours and awards:
NIBIT Clinical Science Award 2020
ESMO European Lung Cancer Conference (ELCC) Merit Award 2019
Award "Best oral presentation" at National Congress of Italian Association of Medical Oncology (2016)
Award " Support to worthy young doctors actively involved in projects for diagnosis and cure of severe diseases" by the Giancarlo Quarta ONLUS Foundation (2014)

Full text publications:
"Immune-checkpoint inhibitors in advanced non-small cell lung cancer with uncommon histology." Manglaviti S, Brambilla M, Signorelli D, Ferrara R, Lo Russo G, Proto C, **Galli G**, De Toma A, Occhipinti M, Viscardi G, Beninato T, Zattarin E, Bini M, Lobefaro R, Massa G, Bottiglieri A, Apollonio G, Sottotetti E, Di Mauro RM, Trevisan B, Ganzinelli M, Fabbri A, de Braud F, Garassino MC, Prelaj A. *[Accepted for publication by Clin Lung Can on 24/06/2021].*

"Patient preferences for lung cancer treatments: a study protocol for a preference survey using discrete choice experiment and swing weighting." Monzani D, Petrocchi S, Oliveri S, Veldwijk J, Janssens R, Bailo L, Smith M, Smith IP, Schoefs E, Nackaerts K, Vandevelde M, Louis E, Decaluwe H, Deleyn P, Declerck H, Katz EG, Petrella F, Casiraghi M, Durosini I, **Galli G**, Garassino MC, de Wit A, Pravettoni G, Huys I. [*Accepted for publication by Front Med on 21/06/2021].*

"Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM)." Conforti F, Marino M, Vitolo V, Spaggiari L, Mantegazza R, Zucali P, Ruffini E, di Tommaso L, Pelosi G, Barberis M, Petrini I, Palmieri G, Pasello

G, **Galli G**, Berardi R, Garassino M, Filosso P, Alloisio M, Scorsetti M, Orecchia R, Pala L, Abatedaga L, Cinieri S, De Pas T. [*Accepted for publication by ESMO Open on 24/05/2021].*

“Evaluation of drug – drug interactions in EGFR-mutated non small cell lung cancer patients during treatment with tyrosine kinase inhibitors.” Occhipinti M, Brambilla M, **Galli G**, Manglaviti S, Giammaruco M, Prelaj A, Ferrara R, De Toma A, Proto C, Beninato T, Zattarin E, Lo Russo G, Gelibter AJ, Simmaco M, Garassino MC, Marchetti P, Preissner R. *[Accepted for publication by J Person Med on 11/05/2021].*

“Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.” De Toma A, Lo Russo G, Signorelli D, Pagani F, Randon G, **Galli G**, Prelaj A, Ferrara R, Proto C, Ganzinelli G, Zilembo N, de Braud F, Garassino MC. *[Accepted for publication by Crit Rev Onco Hematol on 12/03/2021].*

“Beyond first-line immunotherapy: potential therapeutic strategies based on different pattern progressions”. Prelaj A, Pircher CC, Massa G, Martelli V, Corrao G, Lo Russo G, Proto C, Ferrara R, **Galli G**, De Toma A, Genova C, Jereczek-Fossa BA, Garassino MC, Rebuzzi SE. *[Accepted for publication by Cancers on 12/03/2021].*

"Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the Expanded Access Program." Bottiglieri A, Proto C, Lo Russo G, Signorelli D, Ferrara R, **Galli G**, De Toma A, Viscardi G, Brambilla M, Lobefaro R, Nichetti F, Manglaviti S, Occhipinti M, Labianca A, Ganzinelli M, Gallucci R, Zilembo N, Greco GF, Torri V, de Braud F, Garassino MC. *[Accepted for publication by Eur J Can on 08/03/2021].*

“What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences.” Petrocchi S, Janssens R, Oliveri S, Arnou R, Durosini I, Guiddi P, Louis E, Vandevelde M, Nackaerts K, Smith M, **Galli G**, De Marinis F, Gianoncelli L, Pravettoni G, Huys I. *[Accepted for publication by Front Pharmacol on 11/01/2021].*

“Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol.” Durosini I, Janssens R, Arnou R, Veldwijk J, Smith M, Monzani D, Smith I, **Galli G**, Garassino MC, Katz EG, Bailo L, Louis E, Vandevelde M, Nackaerts K, de Wit GA, Pravettoni G, Huys I. *[Accepted for publication by Front Publ Health on 08/01/2021].*

“Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy.” De Toma A, Lo Russo G, Signorelli D, Ferrara R, Prelaj A, **Galli G**, Viscardi G, Trevisan B, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Proto C. *Eur Oncol Hematol* 2020; 6(1):39–43. doi: 10.17925/EOH.2020.16.1.39

“Circulating biomarkers in malignant pleural mesothelioma management.” Viscardi G, Di Natale D, De Toma A, Brambilla M, Lobefaro R, **Galli G**, Prelaj A, Lo Russo G. *[Accepted for publication by Explor Targ Anti-tum Ther on 08/12/2020].*

“Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: the role of clinical-pathological variables and inflammatory biomarkers.” Lobefaro R, Viscardi G, Di Liello R, Massa G, Iacovino ML, Sparano F, Della Corte CM, Ferrara R, Signorelli D, Proto C, Prelaj A, **Galli G**, De Toma A, Brambilla M, Ganzinelli M, Trevisan B, Ciardiello F, de Braud F, Morgillo F, Garassino MC, Lo Russo G. *[Accepted for publication by Lung Cancer on 19/12/2020]*

“Beyond LKB1 mutations in Non-Small Cell Lung Cancer: defining LKB1less phenotype to optimize patient selection and treatment.” Borzi C, **Galli G**, Ganzinelli M, Signorelli D, Vernieri C, Garassino MC, Sozzi G, Moro M. *Pharmaceuticals (Basel),* 2020; 13;13(11):385. doi: 10.3390/ph13110385.

“SMO mutations confer poor prognosis in malignant pleural mesothelioma.” Signorelli D, Proto C, Botta L, Trama A, Tiseo M, Pasello G, Lo Russo G, Fabbri A, Imbimbo M, Busico A, Prelaj A, Ferrara R, **Galli G**, De Toma A, Tamborini E, Pastorino U, de Braud F, Gatta G, Garassino MC, Ganzinelli M. *Transl Lung Cancer,* 2020; 9(5):1940–1951. doi:10.21037/tlcr-20-231

“Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system.” Prelaj A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Mensah M, **Galli G**, De Toma A, Viscardi G, Brambilla M, Lobefaro R, Trevisan B, Trovò F, Torri V, Sozzi G, Garassino MC, Boeri M. *Transl Lung Cancer Res* 2020 ;9(3):617-628. doi:10.1097/CJI.0000000000000340

“Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non‐Small Cell Lung Cancer With a PD-L1 Expression ⩾50%.” Metro G, Banna GL, Signorelli D, Gili A, Galetta D, **Galli G**, Economopoulou P, Roila F, Friedlaender A, Camerini A, Christopoulou A, Cantale O, De Toma A, Pizzutilo P, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Giannarelli D, Mountzios G, Addeo A. *J Immunother* 2020;43:299–306. doi:10.1016/j.lungcan.2020.05.007

“Accuracy of pathologic diagnosis for thymic epithelial tumors: a brief report from an Italian reference Center.” **Galli G**, Trama A, Abate-Daga L, Brambilla M, Garassino MC, Fabbri A. *Lung Cancer*, 2020;

146:66-69. doi:10.1016/j.cllc.2020.01.005

"DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation." Prelaj A, Lo Russo G, Proto C, Signorelli D, Ferrara R, **Galli G**, De Toma A, Randon G, Pagani F, Trevisan B, Ganzinelli M, Zilembo N, Montrone M, Longo V, Pesola F, Pizzutilo P, Del Bene G, Varesano N, Galetta D, Torri V, Garassino MC, Di Maio M, Catino A. *Clin Lung Cancer* , 2020; 21(5):e337-e348. doi:10.1136/esmoopen-2020-000748

"LKB1 mutations are not associated with the efficacy of first- and second-line chemotherapy in patients with advanced non-small cell lung cancer (aNSCLC): a post hoc analysis of the TAILOR trial". Vernieri C, Ganzinelli M, Rulli E, Farina G, Bettini AC, Bareggi C, Rosso L, Signorelli D, **Galli G**, Lo Russo G, Proto C, Moro M, Indraccolo S, Busico A, Sozzi G, Torri V, Marabese M, Broggini M, Garassino MC. *ESMO Open*, 2020; 5(3): e000748.

"Is there an interplay between Immune Checkpoint Inhibitors, thromboprophylactic treatments and thromboembolic events? Mechanisms and impact in Non-Small Cell Lung Cancer patients." Nichetti F, Ligorio F, Zattarin E, Signorelli D, Prelaj A, Proto C, **Galli G**, Marra A, Apollonio G, Porcu L, de Braud F, Lo Russo G, Ferrara R, Garassino MC. *Cancers (Basel)*,2019; 12(1):67. doi:10.3390/cancers12010067

"EPSILoN: a prognostic score for immunotherapy in advanced non-small-cell lung cancer: a validation cohort." Prelaj A, Ferrara R, Rebuzzi SE, Proto C, Signorelli D, **Galli G**, De Toma A, Randon G, Pagani F, Viscardi G, Brambilla M, Trevisan B, Ganzinelli M, Martinetti A, Gallucci R, Di Mauro RM, Molino G, Zilembo N, Torri V, de Braud F, Garassino MC, Lo Russo G. *Cancers (Basel),* 2019; 11(12):1954. doi:10.3390/cancers11121954

"Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer". Romeo MAL, Garassino MC, Moiola L, **Galli G**, Comi G, Martinelli V, Filippi M. *J Neurol* 2019; 266(12):3163-3166. doi: 10.1007/s00415-019-09562-z.

"Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer." Galli G, De Toma A, Pagani F, Randon G, Trevisan B, Prelaj A, Ferrara R, Proto C, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. *Lung Cancer* 2019; 137:38-42. doi: 10.1016/j.lungcan.2019.08.030. doi:10.1016/j.lungcan.2019.08.030.

"Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer." **Galli G**, Proto C, Cossa M, Valeri B, Sdao S, Signorelli D, Imbimbo M, de Braud F, Garassino MC, Lo Russo G. *Tumori J,* 2019; 105(6):NP57-NP62. doi:10.1177/0300891619872546.

"Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study." Fucà G, Mariani L, Lo Vullo S, **Galli G**, Berardi R, Di Nicola M, Vernieri C, Morelli D, Dotti K, Fiordoliva I, Rinaldi S, Gavazzi C, Pietrantonio F, Platania M, de Braud F. *Sci Rep* 2019; 9(1):12993. doi: 10.1038/s41598-019-49601-3. doi:10.1038/s41598-019-49601-3.

"Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patients." De Santis MC, La Rocca E, Meneghini E, Bregni G, Di Lorenzo G, **Galli G**, Di Nicola M, Folli S, Gennaro M, Pruneri G, Paolini B, Daidone MG, de Braud F,1 Apolone G, Sant M, Di Cosimo S. *Clin Transl Oncol,* 2019; 22(5):786-792. doi:10.1007/s12094-019-02188-7.

"Characterization of patients with metastatic Non Small Cell Lung Cancer obtaining Long Term Benefit from Immunotherapy." **Galli G**, Proto C, Signorelli D, Imbimbo M, Ferrara R, Prelaj A, De Toma A, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. *Front Oncol* 2019; 15(23):2743-2757. doi: 10.2217/fon-2019-0055.

"The prognostic role of TNM staging compared to Tumor volume and Number of Pleural Sites in malignant pleural mesothelioma." Proto C, Signorelli D, Mallone S, Prelaj A, Lo Russo G, Imbimbo M, **Galli G**, Ferrara R, Ganzinelli M, Leuzzi G, Greco FG, Calareso G, Botta L, Gatta G, Garassino MC, Trama A. *Clin Lung Can* 2019; 20(6):e652-e660. doi: 10.1016/j.cllc.2019.06.019.

"Association between Antibiotic-Immunotherapy Exposure Ratio and outcome in metastatic Non Small Cell Lung Cancer." **Galli G**, Triulzi T, Proto C, Signorelli D, Imbimbo M, Poggi M, Fucà G, Ganzinelli M, Vitali M, Palmieri D, Tessari A, de Braud F, Garassino MC, Colombo MP, Lo Russo G. *Lung Cancer* 2019; 132:72-78. doi: 10.1016/j.lungcan.2019.04.008.

"Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out." Proto C, Ferrara R, Signorelli D, Lo Russo G, **Galli G**, Imbimbo M, Prelaj A, Zilembo N, Ganzinelli M, Pallavicini L, De Simone I, Colombo MP, Sica A, Torri V, Garassino MC. *Cancer Treat Rev* 2019; 75:39-51. doi: 10.1016/j.ctrv.2019.03.004.

"Combination of immunotherapy and brain radiotherapy in metastatic melanoma: a retrospective analysis." **Galli G**, Cavalieri S, Di Guardo LA, Cimminiello C, Nichetti F, Corti F, Garcia MA, Iacovelli NA, Fallai C, de Braud F, Platania M, Del Vecchio M. *Oncol Res Treat* 2019; 42(4):186-194. doi:

10.1159/000497211.

"Exploiting metformin plus/minus cyclic FAsting Mimicking diet (FMD) to improve the efficacy of platinum-pemetrexed chemotherapy in advanced LKB1-inactivated lung adenocarcinoma: the FAME trial." Vernieri C, Signorelli D, **Galli G**, Ganzinelli M, Moro M, Fabbri A, Tamborini A, Marabese M, Caiola E, Broggini M, Hollander L, Gallucci R, Vandoni G, Gavazzi C, Triulzi T, Colombo MP, Rizzo AM, Corsetto P, Pruneri G, de Braud F, Sozzi G, Torri V, Garassino MC. *Clin Lung Can* 2018; 20(3):e413-e417. doi: 10.1016/j.cllc.2018.12.011.

"MicroRNAs for the diagnosis and management of malignant pleural mesothelioma: a literature review." Palmieri D, Lo Russo G, Tessari A, Capece M, **Galli G**, de Braud F, Garassino MC. *Front Oncol* 2018 ; 8:650. doi: 10.3389/fonc.2018.00650.

"Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors." Fucà G, **Galli G**, Poggi M, Lo Russo G, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, Vernieri C, Balsari A, de Braud F, Garassino MC, Signorelli D. *Esmo Open* 2018; 4:e000457. doi: 10.1136/esmoopen-2018-000457.

"Low baseline serum sodium concentration is associated with poor clinical outcomes in metastatic Non-Small Cell Lung Cancer patients treated with immunotherapy." Fucà G, **Galli G**, Poggi M, Lo Russo G, Proto C, Imbimbo M, Vitali M, Ganzinelli M, Lanti C, Molino G, Stangoni F, Zilembo N, de Braud F, Garassino MC, Signorelli D. *Targ Oncol* 2018; 13(6):795-800. doi: 10.1007/s11523-018-0599-5.

"Best practices for the management of thymic epithelial tumors: a position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)." Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G, Fiore M, Franceschini D, Pasello G, Perrino M, Schiavoni M, Pruneri G, Dei Tos AP, Sangalli C, Garassino MC, Berardi R, Alessi A, Calareso G, Petrini I, Scorcorsetti M, Scotti V, Rosso L, Rea F, Pastorino U, Casali PG, Ramella S, Ricardi U, Abate-Daga L, Torri V, Trama A, Palmieri G, Marinox M, Zucali PA, TYME network collaborators (Alloisio M, Apolone G, Ardizzoni A, Benvenuti M, Berruti A, Breda C, Buzzoni C, Calabrese F, Caraceni A, Cardillo G, Casadio C, Cassi E, Caterino M, Cecere FL, Chiti A, Crippa A, Curcio C, de Braud F, De Pas T, Di Tommaso L, Evoli A, Facciolo F, **Galli G**, Lopez I, Lo Russo G, Spinelli L, Luzzi L, Mantovani C, Marchianò A, Margaritora S, Monaco R, Morandi U, Novellino L, Piras MT, Porcu L, Priola A, Proto C, Ratto GB, Rena O, Rinaldi S, Roca E, Rocco G, Ruffini E, Signorelli D, Solli P, Spaggiari L, Stefani A, Veltri A, Vespro V, Zilembo N. *Can Treat Rev* 2018; 71:76-87. doi: 10.1016/j.ctrv.2018.10.001.

"Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: the ASTER study." Mariani G, **Galli G**, Cavalieri S, Valagussa P, Bianchi GV, Capri G, Cresta S, Ferrari L, Damian S, Duca M, de Braud F, Moliterni A. *The Breast J* 2018; 25(2):273-242. doi: 10.1111/tbj.13197.

"Vitamin D in melanoma: controversies and potential role in combination with immune check-point inhibitors." Stucci LS, D'Oronzo S, Tucci M, Macerollo A, Ribero S, Spagnolo F, Marra E, Picasso V, Orgiano L, Marconcini R, De Rosa F, Di Guardo L, **Galli G**, Gandini S, Palmieri G, Queirolo P, Silvestris F. *Can Treat Rev* 2018; 69:21-28. doi: 10.1016/j.ctrv.2018.05.016.

"The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST." Inno A, Lo Russo G, Salgarello M, Corrao G, Casolino R, **Galli G**, Modena A, Romano L, Pusceddu S, Greco FG, Garassino MC, Gori S. *Tumori* 2018; 104(2):88-95. doi: 10.1177/0300891618766173.

"Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: a case series and literature review." **Galli G**, Corrao G, Imbimbo M, Proto C, Signorelli D, Ganzinelli M, Zilembo N, Vitali M, de Braud F, Garassino MC, Lo Russo G. *Lung Can* 2018; 115:135-142. doi: 10.1177/0300891618766173.

"The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2 positive breast cancer: results from Neo-ALTTO." Di Cosimo S, Campbell C, Azim Jr HA, **Galli G**, Bregni G, Curigliano G, Criscitiello C, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, NG WMJ, Colleoni M, Ferro A, Naume BJ, Patel A, Huober J, Piccart-Gebhart MJ, Baselga J and de Azambuja E. *Eur J Can* 2018; 89:42-48. doi: 10.1177/0300891618766173.

"Clinical implications for pro-GRP in small cell lung cancer. A single center experience." Cavalieri S, Morelli D, Martinetti A, **Galli G,** Nichetti F, de Braud F, Platania M. *Int J Biol Markers* 2017; 33(1):55-61. doi: 10.5301/ijbm.5000305.

"Neoadjuvant chemotherapy exerts selection pressure towards luminal phenotype breast cancer." **Galli G,** Bregni G, Cavalieri S, Porcu L, Baili P, Hade A, Di Salvo F, Sant M, Agresti R, Gennaro M, Folli S, De Santis MC, Paolini B, Carcangiu ML, de Braud F, Di Cosimo S. *Breast Care* 2017;12:391-394. doi: 10.1159/000479582.

"Disease-free interval in metastatic breast cancer patients undergoing complete remission:

implications of cross-sectional study design and biologic considerations about disease history." **Galli G**, Tessari A, Di Cosimo S. *Breast Cancer* 2017; 24(3):491-492. doi: 10.1007/s12282-017-0766-z.

"Complete remission in metastatic breast cancer: expecting the unexpected - Results of a cross-sectional study." **Galli G**, Tessari A, Porcu L, Bregni G, Paolini B, Carcangiu ML, Gennaro M, De Sanctis MC, Lozza L, de Braud F, Di Cosimo S. *Breast Cancer* 2017; 24(4):635-641. doi: 10.1007/s12282-017-0751-6.

"HER2-positive neuroendocrine breast cancer: case report and review of literature." Gevorgyan A, Bregni G, **Galli G**, Zanardi E, de Braud F, Di Cosimo S. *Breast Care* 2016; 11:424-426. doi: 10.1159/000453572.

"Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer." Gevorgyan A, Bregni G, **Galli G**, Ganzinelli M, Martinetti A, Lo Vullo S, Mariani L, Festinese F, Sottotetti E, de Braud F, Di Cosimo S. *Tumori* 2016; 102(4):e11-14. doi: 10.5301/tj.5000515.

"Trastuzumab cardiac toxicity: a problem we put our heart into." Bregni G, **Galli G**, Gevorgyan A, de Braud F, Di Cosimo S. *Tumori* 2016;102(1):1-5. doi: 10.5301/tj.5000393.

"TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma." Verzoni E, Grassi P, Montone R, **Galli G**, Necchi A, Procopio G. *Tumori* 2015; 101(6):701-703. doi: 10.5301/tj.5000335.

"Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies." Serpico D, Porcu L, Tessari A, Gevorgyan A, Bregni G, **Galli G**, de Braud F, Torri V, Di Cosimo S. *Clin Transl Oncol* 2015; 17(7):530-538. doi: 10.1007/s12094-015-1274-2.

"Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patients." Procopio G, Testa I, Verzoni E, Iacovelli R, Grassi P, **Galli G**, de Braud F, Saravia D, Salvioni R. *Oncology* 2015; 88(3):133-138. doi: 10.1159/000367809.

Abstract publications

“Lipid metabolism shapes the efficacy of immunotherapy in non small cell lung cancer patients.” **Galli G**, Corsetto PA, Proto C, Lo Russo G, Ganzinelli M, Rulli E, Legramandi L,Morelli D,Ferrara R, Prelaj A, Signorelli D, De Toma A, Viscardi G, Brambilla M, Labianca A, Manglaviti S, Occhipinti M, Sottotetti E, Sangaletti S, Vingiani A, Colombo MP, Rizzo AM, Sica A, Torri V, de Braud F, Garassino MC. *[Accettato come presentazione orale a NIBIT 2020].*

“Impact of multidisciplinary baseline evaluation for thymic epithelial tumors: experience from an Italian reference Center.” Brambilla M, Abadetaga L, Bosisio M, Borreani C, Eigenmann M, Manglaviti S, Nichetti F, Lobefaro R, Occhipinti M, Labianca A, De Toma A, Viscardi G, Prelaj A, Ferrara R, Signorelli D, Proto C, Lo Russo G, Zilembo N, de Braud F, Garassino MC, **Galli G**. *Tumori J* 2020; 106(Suppl 2):14. doi:10.1177/0300891620953388.

“Hyperprogressive disease upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts).” Ferrara R, Facchinetti F, Calareso G, Kasraoui I, Signorelli D, Proto C, Prelaj A, Naltet C, Levaud P, Desmaris R, **Galli G**, Viscardi G, De Toma A, Martinetti A, Barlesi F, Soria JC, Planchard D, Garassino MC, Besse B, Lo Russo G. *Ann Oncol* 2020; 31(Suppl 4):S826. doi:10.1016/j.annonc.2020.08.1592 .

“Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the Expanded Access Program.” Prelaj A, Bottiglieri A, Proto C, Lo Russo G, Signorelli D, Ferrara R, **Galli G**, De Toma A, Viscardi G, Brambilla M, Lobefaro R, Manglaviti S, Occhipinti M, Labianca A, Gallucci R, Molino G, Zilembo N, Greco GF, Torri V, Garassino MC. *Ann Oncol* 2020; 31(Suppl 4):S882). doi:10.1016/j.annonc.2020.08.1702.

“Chemotherapy followed by immunotherapy compared to reverse sequence in NSCLC with PD-L1 low expression: PFS2 analysis.” Brambilla M, Nichetti F, Lobefaro R, **Galli G**, De Toma A, Viscardi G, Prelaj A, Ferrara R, Proto C, Signorelli D, Bottiglieri A, Massa G, Trevisan B, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. *Ann Oncol* 2020; 31(Suppl 4):S848. doi:10.1016/j.annonc.2020.08.1626.

“Immune checkpoint inhibitors in advanced NSCLC patients with poor performance status: The role of clinicalpathological variables and inflammatory biomarkers in a real world experience.” Lobefaro R, Viscardi G, Di Liello R, Massa G, Iacovino ML, Sparano F, Della Corte CM, Ferrara R, Signorelli D, Proto C, Prelaj A, **Galli G**, De Toma A, Brambilla M, Ganzinelli M, Trevisan B, de Braud F, Morgillo F, Garassino MC, Lo Russo G. *Ann Oncol* 2020; 31(Suppl 4):S856-S857. doi:10.1016/j.annonc.2020.08.1643

“Efficacy and safety of immunotherapy in non-small cell lung cancer patients with poor performance status.” Lobefaro R, Viscardi G, Di Liello R, Massa G, Iacovino ML, Sparano F, Ferrara R, Signorelli D,

Proto C, Prelaj A, **Galli G**, De Toma A, Brambilla M, Ganzinelli M, Trevisan B, Bottiglieri A, de Braud F, Morgillo F, Garassino MC, Lo Russo G. *J Clin Oncol* 2020; 38(Suppl 15):e21601. doi:10.1200/JCO.2020.38.15_suppl.e21601.

"A plasma miRNA signature classifer identifes PD-L1 ⩾ 50% NSCLC nonresponders to immune checkpoint inhibitors." Proto C, Prelaj A, Verri C, Signorelli D, Lo Russo G, Ferrara R, **Galli G**, Trevisan B, Mavis M, de Braud F, Garassino MC, Sozzi G, Boeri M. *J Clin Oncol* 2020; 37(Suppl 15):9096. doi:10.1200/JCO.2019.37.15_suppl.9096 .

"Circulating and tumor-associated neutrophil subtypes discriminate hyperprogressive disease (HPD) from conventional progression (PD) upon immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients (pts) and in vivo models." Ferrara R, Lo Russo G, Signorelli D, Proto C, Prelaj A, **Galli G**, De Toma A, Viscardi G, Lobefaro R, Brambilla M, Talarico G, Bassani B, Spanò SM, Molino G, Zilembo N, Ganzinelli M, Vitale S, Colombo MP, Garassino MC, Sangaletti S. *J Clin Oncol* 2020; 37(Suppl 15):9547. doi:10.1200/JCO.2020.38.15_suppl.954.

"Circulating and tumor associated neutrophil subtypes correlate with hyperprogressive disease (HPD) upon immunecheckpoint inhibitors (ICI) in advanced non-small cell lung cancer (aNSCLC) patients (pts) and in vivo models." Ferrara R, Proto C, Lo Russo G, Signorelli D, Prelaj A, **Galli G**, Zilembo N, De Toma A, Viscardi G, Lobefaro R, Brambilla M, Ganzinelli M, Molino G, Talarico G, Garassino MC, Colombo MP, Sangaletti S. *Cancer Res* 2020; 80(Suppl 16):4480. doi:10.1158/1538-7445.AM2020-4480.

"Accuracy of pathologic diagnosis of thymic epithelial tumors: a single Institution experience." **Galli G**, Fabbri A, Ferrara R, Prelaj A, Proto C, Signorelli D, De Toma A, Pagani F, Zilembo N, Ganzinelli M, Abate-Daga L, Pruneri G, de Braud F, Garassino M, Lo Russo G. *Tumori J* 2019; 106(6S):107. doi:10.1177/0300891619872589 .

"Clinical characteristics and biological profile of Lung Enteric Adenocarcinoma." Imbimbo M, **Galli G**, Busico A, Perrone F, Tamborini E, Fabbri A, Marano G, Biganzoli D, Ferrara R, Lo Russo G, Prelaj A, Proto C, Zilembo N, De Toma A, Ganzinelli M, Biganzoli E, Pruneri G, de Braud F, Garassino MC, Signorelli D. *Tumori J* 2019; 106(6S):107. doi:10.1177/0300891619872589.

"Immune Checkpoint Inhibitors in the elderly with Non-Small Cell Lung Cancer: efficacy and safety." Randon G, De Toma A, Pagani F, Trevisan B, Prelaj A, Ferrara R, Proto C, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G, **Galli G**. Tumori J 2019; 106(6S):89. doi:10.1177/0300891619872589.

"Using plasma microRNAs as biomarkers of resistance to immune checkpoint inhibitors in PD-L1>50% advanced NSCLC." Proto C, Prelaj A, Verri C, Signorelli D, Lo Russo G, Ferrara R, **Galli G**, Trevisan B, Mavis M, de Braud F, Garassino MC, Sozzi G, Boeri M. *Tumori J* 2019; 106(6S):90. doi: 10.1177/0300891619872589

"DeMo score: a prospective evaluation of a prognostic clinco-molecular composite score in patient with advanced NSCLC treated with immunotherapy. "Prelaj A, Proto C, Lo Russo G, Signorelli D, Ferrara R, **Galli G**, De Toma A, Randon G, Pagani F, Travisan B, Ganzinelli M, Zilembo N, De Braud F, Mensah M, Torri V, Garassino MC, Sozzi G, Boeri M. *Tumori J* 2019; 106(6S):92. doi: 10.1177/0300891619872589

"Accuracy of pathologic evaluation for thymic epithelial tumors in an Italian reference Centre." **Galli G**, Fabbri A, Ferrara R, Prelaj A, Proto C, Signorelli D, De Toma A, Pagani F, Zilembo N, Ganzinelli M, Abate-Daga L, Pruneri G, de Braud F, Garassino MC, Lo Russo G. *Ann Oncol* 2019; 30(suppl_5): v747-v755. 10.1093/annonc/mdz266 .

"Prognostic role of CD73 in metastatic Non Small Cell Lung Cancer according to the presence of driver alterations." **Galli G**, Ferrara R, Pagani F, De Toma A, Lo Russo G, Signorelli D, Prelaj A, Zilembo N, Ganzinelli M, Brich S, Fabbri A, Sangaletti S, Pruneri G, Colombo M, de Braud F, Garassino MC, Proto C. *Ann Oncol* 2019; 30(suppl_5):v797-v815. 10.1093/annonc/mdz269.

"Efficacy and safety of Immunotherapy in elderly patients with Non-Small Cell Lung Cancer." **Galli G**, De Toma A, Pagani F, Randon G, Trevisan B, Prelaj A, Ferrara R, Proto C, Signorelli S, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. *J Thorac Oncol* 2019; 14(suppl 10):S454. https://doi.org/10.1016/j.jtho.2019.08.941.

"Clinical and biological characterization of Lung Enteric Adenocarcinoma." **Galli G**, Imbimbo M, Busico A, Perrone F, Tamborini E, Fabbri A, Marano G, Biganzoli D, Ferrara R, Lo Russo G, Prelaj A, Proto C, Zilembo N, De Toma A, Ganzinelli M, Biganzoli E, Pruneri G, de Braud F, Garassino MC, Signorelli D. *J Thorac Oncol* 2019; 14(suppl 10):S770. https://doi.org/10.1016/j.jtho.2019.08.1654.

"Impact of cholesterolemia and body mass index on outcome of metastatic Non Small Cell Lung

Cancer treated with immunotherapy." **Galli G**, Corsetto PA, Ferrara R, Prelaj A, Proto C, Signorelli D, Zilembo N, De Toma A, Pagani F, Randon G, Ganzinelli M, Sica A, de Braud F, Garassino MC, Lo Russo G. *J Clin Oncol* 2019; 15 suppl: e20691. DOI: 10.1200/JCO.2019.37.15_suppl.e20691.

"Immune-checkpoints inhibitors in metastatic Non Small Cell Lung Cancer with rare histology." Signorelli D, Ferrara R, Proto C, Lo Russo G, Imbimbo M, **Galli G**, De Toma A, Pagani F, Randon G, Fucà G, Trevisan B, Ganzinelli M, Zilembo N, Fabbri A, de Braud F, Garassino MC, Prelaj A. *J Clin Oncol* 2019; 15 suppl:9106. DOI: 10.1200/JCO.2019.37.15_suppl.9106.

"A plasma miRNA signature classifier identifies PD-L1≥50% NSCLC non responders to immune-checkpoint inhibitors." Proto C, Prelaj A, Verri C, Signorelli D, Lo Russo G, Ferrara R, **Galli G**, Trevisan B, Mavis M, de Braud F, Garassino MC, Sozzi G, Boeri M. *J Clin Oncol* 2019; 15 suppl:9096. DOI: 10.1200/JCO.2019.37.15_suppl.9096.

"Prognostic score for second or further line immunotherapy in advanced non-small-cell lung cancer (aNSCLC): an external validation." Prelaj A, Lo Russo G, Proto C, Signorelli D, Ferrara R, **Galli G**, De Toma A, Randon G, Zilembo N, Trevisan B, Montrone M, Longo V, Pesola F, Varesano N, Del Bene G, Pizzutilo P, Galetta D, Garassino MC, Di Maio M, Catino A. *J Clin Oncol* 2019; 15 suppl:14077. DOI: 10.1200/JCO.2019.37.15_suppl.14077.

"Characterization of patients with metastatic Non Small Cell Lung Cancer obtaining Long Term Benefit from Immunotherapy." **Galli G**, Proto C, Signorelli D, Imbimbo M, Ferrara R, Prelaj A, De Toma A, Randon G, Trevisan B, Ganzinelli M, Zilembo N, Garassino MC, Lo Russo G. *Ann Oncol* 2019; 30(suppl 2):ii56. https://doi.org/10.1093/annonc/mdz063.048.

"Metformin +/- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: the FAME trial." **Galli G**, Vernieri C, Signorelli D, Ganzinelli M, Moro M, Fabbri A, Tamborini E, Marabese M, Caiola E, Broggini M, Hollander L, Gallucci R, Gavazzi C, Rizzo AM, Corsetto P, Pruneri G, de Braud F, Sozzi G, Torri V, Garassino MC. *Ann Oncol* 2019; 30(suppl 2):ii38-68. 10.1093/annonc/mdz063.

"EPSILoN score: a predictive score using clinical and blood biomarkers in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy." Prelaj A, Lo Russo G, Signorelli D, Ferrara R, Imbimbo M, **Galli G**, De Toma A, Randon G, Brambilla M, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Proto C. *Ann Oncol* 2019; 30(suppl 2):ii38-68. 10.1093/annonc/mdz063.

"Is "hyper-progression" a relevant clinical item for patient with solid tumours candidate to check-point inhibitor treatment?" De Braud F, Di Nicola M, Damian S, Cresta S, Duca M, Indini A, Di Bartolomeo M, **Galli G**, Farè E, Verzoni E. *Ann Oncol* 2018; 29(suppl 3):ii5. DOI: 10.1093/annonc/mdy046.018.

"Concomitant immunotherapy and radiotherapy for metastatic non small cell lung cancer: a single Institution experience." **Galli G**, Botta L, Poggi M, Fucà G, Imbimbo M, Lo Russo G, Proto C, Vitali M, Zilembo N, Ganzinelli M, de Braud F, Garassino MC, Signorelli D. Tumori J 2018; 104(4S):94. doi:10.1177/0300891618796945 .

"Prognostic and predictive role of hyponatremia in patients with metastatic non-small cell lung cancer treated with immunotherapy." Fucà G, Poggi M, **Galli G**, Imbimbo M, Lo Russo G, Proto C, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Vitali M. Tumori J 2018; 104(4S):103. doi:10.1177/030089161879694.

"Basal lymphopenia as a potential predictor of benefit from immunotherapy in metastatic non small cell lung cancer." **Galli G**, Poggi M, Fucà G, Lo Russo G, Proto C, Signorelli D, Vitali M, Ganzinelli M, Zilembo N, de Braud F, Garassino M, Imbimbo M. *Ann Oncol* 2018; 29(suppl 8):viii493-viii547. 10.1093/annonc/mdy292.

"Effects of antibiotic use during immunotherapy in metastatic non small cell lung cancer ." **Galli G**, Poggi M, Fucà G, Imbimbo M, Proto C, Signorelli D, Vitali M, Zilembo N, Ganzinelli M, de Braud F, Garassino M, Lo Russo G. *Ann Oncol* 2018; 29(suppl 8):mdy292.088. https://doi.org/10.1093/annonc/mdy292.088.

"Impact of early steroids use on clinical outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors." Fucà G, Poggi M, **Galli G**, Imbimbo M, Lo Russo G, Signorelli D, Vitali M, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Proto C. *Ann Oncol* 2018; 29(suppl 8):mdy292.012. https://doi.org/10.1093/annonc/mdy292.012.

"Management of CNS Mets in the Era of CNS-Penetrant TKIs (Med Onc and Rad Onco Perspectives)." **Galli G**, Garassino M. *J Thorac Oncol* 2018; 13(10 suppl):S290-S291. DOI: https://doi.org/10.1016/j.jtho.2018.08.182.

"Impact of antibiotics on outcome of metastatic non small cell lung cancer patients treated with immunotherapy." **Galli G**, Poggi M, Fucà G, Imbimbo M, Proto C, Signorelli D, Vitali M, Zilembo N, Ganzinelli M, de Braud F, Garassino M, Lo Russo G. *J Thorac Oncol* 2018; 13(10 suppl):S389. DOI: https://doi.org/10.1016/j.jtho.2018.08.396.

"Effect of early steroids use in advanced NSCLC patients treated with immunotherapy." Fucà G, Poggi

M, **Galli G**, Imbimbo M, Lo Russo G, Proto C, Vitali M, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Signorelli D. *J Thoracic Oncol* 2018; 13(10 suppl):S390. DOI: https://doi.org/10.1016/j.jtho.2018.08.398.

“Effect of basal lymphopenia on outcome of non small cell lung cancer patients treated with immunotherapy.” **Galli G**, Poggi M, Fucà G, Imbimbo M, Lo Russo G, Proto C, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino M, Vitali M. *J Thoracic Oncol* 2018; 13(10 suppl):S468. DOI: https://doi.org/10.1016/j.jtho.2018.08.578.

“Prognostic value of the interval between the last neoadjuvant chemotherapy (CT) administration and breast surgery: Preliminary data of the NeoBracer international observational study.” Cinausero M, **Galli G**, Basile D, Martorana F, De Santo I, Perroud HA, Zenovia Antone N, Campos Gomez S, Gerratana L, Minisini AM, Sant M, Folli S, Campos Gomez KA, Eniu AE, Cismaru A, Arpino G, Vigneri PG, Fasola G, Di Cosimo S, Puglisi F. *J Clin Oncol* 2018; 36(suppl; abstr e12629). DOI: 10.1200/JCO.2018.36.15_suppl.e12629.

“Combination of brain radiotherapy (RT) and immunotherapy (IT) in a single Institution cohort of patients (pts) with metastatic melanoma (MM).” **Galli G**, Cavalieri S, Di Guardo L, Cimminiello C, Corti F, Nichetti F, Garcia M, Tana S, Fallai C, de Braud F, Platania M, Del Vecchio M. *Ann Oncol* 2017; 28 (suppl 11):xi8. https://doi.org/10.1093/annonc/mdx711.008.

“TNM or tumor volume for predicting prognosis in malignant pleural mesothelioma: still an open debate.” Imbimbo M, Proto C, Mallone S, Signorelli D, Greco FG, Calareso G, Botta L, Lo Russo G, Vitali M, Corrao G, **Galli G**, Ganzinelli M, Zilembo N, Pastorino U, Garassino MC, Trama A. *J Thorac Oncol* 2017; 12 (11, suppl 2):S2156–S2157.

“Brain radiotherapy (RT) and immunotherapy (IT) for metastatic melanoma (MM): a retrospective single Institution experience.” **Galli G**, Cavalieri S, Di Guardo L, Cimminiello C, Corti F, Nichetti F, Garcia M, Tana S, Fallai C, de Braud F, Platania M, Del Vecchio M. *Ann Oncol* 2017; 28 (suppl 6):vi68. https://doi.org/10.1093/annonc/mdx428.002.

“Time to surgery after neoadjuvant chemotherapy for early breast cancer.” Cinausero M, **Galli G,** Basile D, Gerratana L, Fasola G, de Braud F, Sant M, Paolini B, Puglisi B, Di Cosimo S. *Ann Oncol* 2017; 28 (suppl 6):vi29. https://doi.org/10.1093/annonc/mdx424.014.

“Long term results of ASTER study, a single Institution phase II trial of sequential chemotherapy (CT) for operable breast cancer (BC).” Mariani G, **Galli G,** Cavalieri S, Valagussa P, Bianchi G, Capri G, Cresta S, Ferrari L, Damian S, Duca M, de Braud F, Moliterni A. *Ann Oncol* 2017; 28 (suppl 6):vi34. https://doi.org/10.1093/annonc/mdx424.033.

“Profiling of peripheral blood T lymphocytes in solid tumor patients undergoing immune checkpoint blockade therapy.” Tassi E, Grazia G, Vegetti C, Cimminiello C, Di Guardo L, Indini A, Galli G, Corrao G, Signorelli D, Proto C, Lo Russo G, Del Vecchio M, Garassino MC, Mortarini R, Anichini A. *EACR Conference Series - Defence is the Best Attack: Immuno-Oncology Breakthroughs Programme Book* 2017; p84.

“Time to surgery in early breast cancer treated with neoadjuvant chemotherapy.” Cinausero M, **Galli G,** Basile D, Gerratana L, Fasola G, de Braud F, Sant M, Paolini B, Di Cosimo S, Puglisi F. *Ann Oncol* 2017; 28(suppl 5):iv49-50. 10.1093/annonc/mdx362.

“CAMLs and CTM in women treated for breast cancer: understanding the clinical value of circulating tumor associated cells.” Di Cosimo S, Bottelli S, Reduzzi C, **Galli G,** Bregni G, Martinetti A, Paolini B, Verderio P, Cappelletti V. *EACR Proceedings Book* 2017; p143.

“Retrospective analysis of patients (pts) with metastatic melanoma (MM) showing long-term response (LTR) to vemurafenib (Vb).” **Galli G**, Di Guardo L, Cimminiello C, Cavalieri S, Rodolfo M, Rivoltini L, Valeri B, Bono A, Tolomio E, Del Vecchio M. *J Clin Oncol* 2017; 35(suppl 13). DOI: 10.1200/JCO.2017.35.15_suppl.e21001.

" Ki67, tumor stage (TS) and axillary node metastases (ANMs): a complex relationship." **Galli G**, Bregni G, Meneghini E, Cavalieri S, Di Salvo F, Amash H, Paolini B, de Braud F, De Santis MC, Sant M, Di Cosimo S. *Ann Oncol* 2016; 27(suppl 4):iv59. https://doi.org/10.1093/annonc/mdw337.02.

" It's not the quality but the quantity: tumor mutation spectrum and response to neoadjuvant therapy in triple negative breast cancer." Di Cosimo S, Dugo M, Appierto V, Cavalieri S, Angeloni V, **Galli G**, Bregni G, Cappelletti V, Paolini B, Perrone E, Tiberio P, de Braud F. *Ann Oncol* 2016; 27(suppl 4):iv70. https://doi.org/10.1093/annonc/mdw337.36.

"Pro-gastrin releasing peptide (pro-GRP) in small cell lung cancer staging." Cavalieri S, Raimondi A, Morelli D, Martinetti A, de Braud F, Agustoni F, Dotti K, **Galli G**, Vernieri C, Fucà G, Peverelli G, Prisciandaro M, Nichetti F, Indelicato P, Lo Russo G, Prinzi N, Garassino M, Platania M. *Ann Oncol* 2016; 27(suppl 4):iv13. https://doi.org/10.1093/annonc/mdw332.34.

"Breast cancer, Ki67, tumor size and axillary nodes relationship: it's complicated." Bregni G, Meneghini E, **Galli G**, Cavalieri S, Di Salvo F, Amash H, Paolini B, de Braud F, De Santis MC, Sant M, Di Cosimo

S. *Ann Oncol* 2016; 27(suppl 6):163P. https://doi.org/10.1093/annonc/mdw364.19.

"Effect of body mass index (BMI) on response to neoadjuvant therapy in human epidermal growth factor receptor 2 (HER2) positive breast cancer (BC): analysis from NeoALLTO trial." **Galli G**, Bradbury I, Cinieri S, Agbor-Tahr D, de Braud F, Baselga J, Huober J, Fumagalli D, Sarp S, Piccart M, de Azambuja E, Di Cosimo S. *Ann Oncol* 2016; 27(suppl 6):191P. https://doi.org/10.1093/annonc/mdw364.47.

"Neo-adjuvant chemotherapy for the treatment of breast cancer exterts a selection pressure toward luminal phenotype." **Galli G**, Porcu L, Baili P, Amash H, Di Salvo F, Bregni G, Agresti R, Gennaro M, De Santis MC, Ferrari B, de Braud F, Di Cosimo S. *Canc Res* 2016; 76 (suppl 4):PI14-PI22.

"Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer according to body mass index." Gevorgyan A, Ganzinelli M, Martinetti A, Lo Vullo S, Mariani L, Festinese F, Sottotetti E, Ferrari B, **Galli G**, de Braud F, Di Cosimo S. *Ann Oncol* 2015; 26(suppl 6):vi12-vi13. https://doi.org/10.1093/annonc/mdv336.31.

" First analysis of ASTER study AT for 3 cycles followed by CMF for 3 cycles as neo or adjuvant chemotherapy in early stage breast cancer. A single institution experience." Mariani G, **Galli G**, Mariani P, Bianchi GV, Capri G, Cresta S, De Benedictis E, Valagussa P, Magazzù D, de Braud F, Moliterni A. *Canc Res* 2013; 73(suppl 24):P312-P313.

Lectures

Virtual XXVIII NIBIT meeting – virtual event, 15-16/10/2020

Thoracic cancer highlights: best of year 2019 – Bologna, 24/01/2020

I Tumori Epiteliali del Timo: stato dell'arte e prospettive future – Milano, 29/11/2019

World Congress on Lung Cancer 2018 – Toronto, 24-26/09/2018

Grandangolo in Oncology: Focus on supportive therapies 2017 – Bologna, 08-09/05/2017

Skin Cancer Master on "Optimization of multidisciplinary treatment of metastatic melanoma and advanced basal skin carcinoma " - Milan, 21-22/11/2016

National Congress of Italian Association of Medical Oncology - Rome, 28-30/10/2016

Authorization to treatment of personal information

I hereby authorize the use of my personal details solely for circulation within the company according to the Italian Legislative Decree n° 196/2003.